AngioDynamics Lifts Outlook Despite Widening 3Q Loss

Dow Jones04-02

By Connor Hart

AngioDynamics raised its full-year outlook after logging higher sales in its fiscal third quarter, though its loss widened as expenses increased.

The medical-technology company said Thursday it now expects sales of $313.5 million to $315.5 million for the year, compared with a prior view of $312 million to $314 million.

It also now expects an adjusted loss of 30 cents a share to 23 cents a share, compared with a prior outlook of 33 cents a share to 23 cents a share.

Analysts polled by FactSet are looking for an adjusted loss of 29 cents a share on sales of $312.9 million.

The new outlook came as AngioDynamics posted a loss of $8.08 million, or 19 cents a share, for its quarter ended Feb. 28. That compares with a loss of $4.41 million, or 11 cents a share, a year earlier.

Stripping out one-time items, the company notched a loss of 7 cents a share. Analysts had expected the company to break even on an adjusted basis.

Total operating expenses increased to $54.4 million from $48.8 million, driven by higher research-and-development and sales-and-marketing costs.

Quarterly sales rose 9% to $78.4 million, topping Wall Street models for $76.8 million.

Medical technology sales climbed 19%, to $37.3 million, while medical device sales ticked up 1.1%, to $41.1 million.

Shares were down 1.3%, at $12.10, in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

April 02, 2026 06:30 ET (10:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624508817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624508817","market":"hk","top_or_hot":-1,"title":"AngioDynamics Lifts Outlook Despite Widening 3Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AngioDynamics raised its full-year outlook after logging higher sales in its fiscal third quarter, though its loss widened as expenses increased. \n</p>\n<p>\n  The medical-technology company said Thursday it now expects sales of $313.5 million to $315.5 million for the year, compared with a prior view of $312 million to $314 million. \n</p>\n<p>\n  It also now expects an adjusted loss of 30 cents a share to 23 cents a share, compared with a prior outlook of 33 cents a share to 23 cents a share. \n</p>\n<p>\n  Analysts polled by FactSet are looking for an adjusted loss of 29 cents a share on sales of $312.9 million. \n</p>\n<p>\n  The new outlook came as AngioDynamics posted a loss of $8.08 million, or 19 cents a share, for its quarter ended Feb. 28. That compares with a loss of $4.41 million, or 11 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, the company notched a loss of 7 cents a share. Analysts had expected the company to break even on an adjusted basis. \n</p>\n<p>\n  Total operating expenses increased to $54.4 million from $48.8 million, driven by higher research-and-development and sales-and-marketing costs. \n</p>\n<p>\n  Quarterly sales rose 9% to $78.4 million, topping Wall Street models for $76.8 million. \n</p>\n<p>\n  Medical technology sales climbed 19%, to $37.3 million, while medical device sales ticked up 1.1%, to $41.1 million. \n</p>\n<p>\n  Shares were down 1.3%, at $12.10, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 06:30 ET (10:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Lifts Outlook Despite Widening 3Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Lifts Outlook Despite Widening 3Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-02 18:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AngioDynamics raised its full-year outlook after logging higher sales in its fiscal third quarter, though its loss widened as expenses increased. \n</p>\n<p>\n  The medical-technology company said Thursday it now expects sales of $313.5 million to $315.5 million for the year, compared with a prior view of $312 million to $314 million. \n</p>\n<p>\n  It also now expects an adjusted loss of 30 cents a share to 23 cents a share, compared with a prior outlook of 33 cents a share to 23 cents a share. \n</p>\n<p>\n  Analysts polled by FactSet are looking for an adjusted loss of 29 cents a share on sales of $312.9 million. \n</p>\n<p>\n  The new outlook came as AngioDynamics posted a loss of $8.08 million, or 19 cents a share, for its quarter ended Feb. 28. That compares with a loss of $4.41 million, or 11 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, the company notched a loss of 7 cents a share. Analysts had expected the company to break even on an adjusted basis. \n</p>\n<p>\n  Total operating expenses increased to $54.4 million from $48.8 million, driven by higher research-and-development and sales-and-marketing costs. \n</p>\n<p>\n  Quarterly sales rose 9% to $78.4 million, topping Wall Street models for $76.8 million. \n</p>\n<p>\n  Medical technology sales climbed 19%, to $37.3 million, while medical device sales ticked up 1.1%, to $41.1 million. \n</p>\n<p>\n  Shares were down 1.3%, at $12.10, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 06:30 ET (10:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2624508817","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624508817","pubTimestamp":1775125800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AngioDynamics raised its full-year outlook after logging higher sales in its fiscal third quarter, though its loss widened as expenses increased.The medical-technology company said Thursday it now expects sales of $313.5 million to $315.5 million for the year, compared with a prior view of $312 million to $314 million.It also now expects an adjusted loss of 30 cents a share to 23 cents a share, compared with a prior outlook of 33 cents a share to 23 cents a share.Analysts polled by FactSet are looking for an adjusted loss of 29 cents a share on sales of $312.9 million.The new outlook came as AngioDynamics posted a loss of $8.08 million, or 19 cents a share, for its quarter ended Feb. 28. That compares with a loss of $4.41 million, or 11 cents a share, a year earlier.Stripping out one-time items, the company notched a loss of 7 cents a share. Analysts had expected the company to break even on an adjusted basis.Total operating expenses increased to $54.4 million from $48.8 million, drive","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"尽管第三季度亏损扩大，AngioDynamics仍上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  AngioDynamics raised its full-year outlook after logging higher sales in its fiscal third quarter, though its loss widened as expenses increased. \n\n\n  The medical-technology company said Thursday it now expects sales of $313.5 million to $315.5 million for the year, compared with a prior view of $312 million to $314 million. \n\n\n  It also now expects an adjusted loss of 30 cents a share to 23 cents a share, compared with a prior outlook of 33 cents a share to 23 cents a share. \n\n\n  Analysts polled by FactSet are looking for an adjusted loss of 29 cents a share on sales of $312.9 million. \n\n\n  The new outlook came as AngioDynamics posted a loss of $8.08 million, or 19 cents a share, for its quarter ended Feb. 28. That compares with a loss of $4.41 million, or 11 cents a share, a year earlier. \n\n\n  Stripping out one-time items, the company notched a loss of 7 cents a share. Analysts had expected the company to break even on an adjusted basis. \n\n\n  Total operating expenses increased to $54.4 million from $48.8 million, driven by higher research-and-development and sales-and-marketing costs. \n\n\n  Quarterly sales rose 9% to $78.4 million, topping Wall Street models for $76.8 million. \n\n\n  Medical technology sales climbed 19%, to $37.3 million, while medical device sales ticked up 1.1%, to $41.1 million. \n\n\n  Shares were down 1.3%, at $12.10, in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 06:30 ET (10:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624508817","isCrawlerRequest":true}